Dr. Douglas C. O'brien is a pharmacist who is specialized in Pharmacotherapy in Sacramento, California. Patients can reach him at 3240 Arden Way, Pharmacy Operations, Sacramento or contact him on 916-486-5113. Active license number of Dr. Douglas C. O'brien is RPH38036 for Pharmacotherapy in California. Dr. Douglas C. O'brien is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Dr. Douglas C. O'brien speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Douglas C. O'brien are as mentioned below.
NPI Number:
1326069758
NPI Enumeration Date:
21 Jul, 2006
NPI Last Update On:
07 Sep, 2023
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Douglas C. O'brien are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
RPH38036
California
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
4851 Brighton Ct, Granite Bay, California
Zip:
95746-6414
Phone Number:
916-797-3936
Fax Number:
--
Patients can reach Dr. Douglas C. O'brien at 3240 Arden Way, Pharmacy Operations, Sacramento, California or can call on phone at 916-486-5113.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.